JP2004520290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520290A5 JP2004520290A5 JP2002546515A JP2002546515A JP2004520290A5 JP 2004520290 A5 JP2004520290 A5 JP 2004520290A5 JP 2002546515 A JP2002546515 A JP 2002546515A JP 2002546515 A JP2002546515 A JP 2002546515A JP 2004520290 A5 JP2004520290 A5 JP 2004520290A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- condition
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 12
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- 229940127219 anticoagulant drug Drugs 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 108090000190 Thrombin Proteins 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000005665 thrombophilia Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0004458A SE0004458D0 (sv) | 2000-12-01 | 2000-12-01 | Pharmaceutically useful compounds |
| SE0100965A SE0100965D0 (sv) | 2001-03-19 | 2001-03-19 | Pharmaceutically-useful compounds |
| SE0101239A SE0101239D0 (sv) | 2001-04-06 | 2001-04-06 | Pharmaceutically useful compounds |
| SE0102921A SE0102921D0 (sv) | 2001-08-30 | 2001-08-30 | Pharmaceutically useful compounds |
| PCT/SE2001/002657 WO2002044145A1 (en) | 2000-12-01 | 2001-11-30 | New mandelic acid derivatives and their use as throbin inhibitors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008006611A Division JP2008138009A (ja) | 2000-12-01 | 2008-01-16 | 新規マンデル酸誘導体とそれらのトロンビン阻害剤としての使用 |
| JP2008006608A Division JP2008156362A (ja) | 2000-12-01 | 2008-01-16 | 新規マンデル酸誘導体とそれらのトロンビン阻害剤としての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004520290A JP2004520290A (ja) | 2004-07-08 |
| JP2004520290A5 true JP2004520290A5 (enExample) | 2008-03-06 |
| JP4177101B2 JP4177101B2 (ja) | 2008-11-05 |
Family
ID=27484527
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002546515A Expired - Fee Related JP4177101B2 (ja) | 2000-12-01 | 2001-11-30 | 新規マンデル酸誘導体とそれらのトロンビン阻害剤としての使用 |
| JP2008006608A Pending JP2008156362A (ja) | 2000-12-01 | 2008-01-16 | 新規マンデル酸誘導体とそれらのトロンビン阻害剤としての使用 |
| JP2008006611A Pending JP2008138009A (ja) | 2000-12-01 | 2008-01-16 | 新規マンデル酸誘導体とそれらのトロンビン阻害剤としての使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008006608A Pending JP2008156362A (ja) | 2000-12-01 | 2008-01-16 | 新規マンデル酸誘導体とそれらのトロンビン阻害剤としての使用 |
| JP2008006611A Pending JP2008138009A (ja) | 2000-12-01 | 2008-01-16 | 新規マンデル酸誘導体とそれらのトロンビン阻害剤としての使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US20070218136A1 (enExample) |
| EP (2) | EP1347955B1 (enExample) |
| JP (3) | JP4177101B2 (enExample) |
| KR (4) | KR100947296B1 (enExample) |
| CN (1) | CN1291975C (enExample) |
| AR (2) | AR035216A1 (enExample) |
| AT (1) | ATE461171T1 (enExample) |
| AU (2) | AU2007203509A1 (enExample) |
| BG (1) | BG66261B1 (enExample) |
| BR (1) | BR0115861A (enExample) |
| CA (1) | CA2436220C (enExample) |
| CY (1) | CY1113487T1 (enExample) |
| CZ (1) | CZ303708B6 (enExample) |
| DE (1) | DE60141603D1 (enExample) |
| DK (1) | DK1347955T3 (enExample) |
| EE (1) | EE05382B1 (enExample) |
| ES (1) | ES2341318T3 (enExample) |
| HU (1) | HU228814B1 (enExample) |
| IL (1) | IL156096A0 (enExample) |
| IS (1) | IS2755B (enExample) |
| MX (1) | MXPA03004794A (enExample) |
| MY (1) | MY136133A (enExample) |
| NO (3) | NO325228B1 (enExample) |
| NZ (1) | NZ526205A (enExample) |
| PL (1) | PL207045B1 (enExample) |
| PT (1) | PT1347955E (enExample) |
| SI (1) | SI1347955T1 (enExample) |
| SK (1) | SK287692B6 (enExample) |
| WO (1) | WO2002044145A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| AR034517A1 (es) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
| SE0201661D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
| SE0201658D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
| SE0201662D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Pharmaceutical combination |
| SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| RU2005128501A (ru) | 2003-02-13 | 2006-04-27 | Веллстат Терапьютикс Корпорейшн (Us) | Соединение для лечения метаболических расстройств |
| GB0306615D0 (en) * | 2003-03-22 | 2003-04-30 | Astrazeneca Ab | New use |
| US7781424B2 (en) * | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| SE0303220D0 (sv) | 2003-11-28 | 2003-11-28 | Astrazeneca Ab | New process |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US7645778B2 (en) | 2005-01-19 | 2010-01-12 | Bristol-Myers Squibb Company | Heteroaryl compounds as P2Y1 receptor inhibitors |
| GB0503672D0 (en) * | 2005-02-23 | 2005-03-30 | Astrazeneca Ab | New process |
| GB0510546D0 (en) * | 2005-05-24 | 2005-06-29 | Astrazeneca Ab | New process |
| AU2006261828A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| WO2007002634A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| DE602006020871D1 (de) | 2005-06-27 | 2011-05-05 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden |
| ATE485269T1 (de) | 2005-06-27 | 2010-11-15 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden |
| US7915429B2 (en) | 2006-01-25 | 2011-03-29 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| WO2007087505A2 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| JP2009525982A (ja) | 2006-02-02 | 2009-07-16 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
| US8044242B2 (en) | 2006-03-09 | 2011-10-25 | Bristol-Myers Squibb Company | 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants |
| EP2061756B1 (en) | 2006-06-08 | 2013-09-25 | Bristol-Myers Squibb Company | 2-aminocarbonylphenylamino-2-phenilacetamides as factor viia inhibitors useful as anticoagulants |
| DE102006033572A1 (de) | 2006-07-20 | 2008-01-24 | Bayer Cropscience Ag | N'-Cyano-N-halogenalkyl-imidamid Derivate |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| TW200827336A (en) * | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
| US8410155B2 (en) | 2006-12-15 | 2013-04-02 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors |
| PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
| AU2008241091B2 (en) | 2007-04-23 | 2013-05-09 | Sanofi-Aventis | Quinoline-carboxamide derivatives as P2Y12 antagonists |
| TW200900033A (en) * | 2007-06-21 | 2009-01-01 | Wen-Qing Li | Automatic brewing machine |
| US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
| EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
| KR101843542B1 (ko) | 2010-02-11 | 2018-03-30 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 ＸＩａ 억제제로서의 마크로사이클 |
| TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子ｘｉａ抑制劑之新穎巨環化合物 |
| TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑 |
| JP6033317B2 (ja) | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| UY34393A (es) | 2011-10-14 | 2013-04-30 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia |
| EA025392B1 (ru) | 2012-08-03 | 2016-12-30 | Бристол-Маерс Сквибб Компани | Дигидропиридон р1 в качестве ингибиторов фактора xia |
| BR112015002081A2 (pt) | 2012-08-03 | 2017-07-04 | Bristol Myers Squibb Co | di-hidropiridona p1 como inibidores de fator xia |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
| NO2760821T3 (enExample) | 2014-01-31 | 2018-03-10 | ||
| UY35971A (es) | 2014-01-31 | 2015-07-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia |
| NO2721243T3 (enExample) | 2014-10-01 | 2018-10-20 | ||
| CN108026083B (zh) | 2015-06-19 | 2021-08-27 | 百时美施贵宝公司 | 作为因子xia抑制剂的二酰胺大环 |
| EP3868753B1 (en) | 2015-07-29 | 2022-12-21 | Bristol-Myers Squibb Company | Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group |
| KR102697816B1 (ko) | 2015-08-05 | 2024-08-21 | 브리스톨-마이어스 스큅 컴퍼니 | 신규 치환된 글리신 유도된 fxia 억제제 |
| CN105294520A (zh) * | 2015-11-23 | 2016-02-03 | 大连九信生物化工科技有限公司 | 一种2-（2’,2’-二氟乙氧基）-6-三氟甲基苯基丙基硫醚的合成工艺 |
| US10752641B2 (en) | 2016-03-02 | 2020-08-25 | Bristol-Myers Squibb Company | Diamide macrocycles having factor XIa inhibiting activity |
| CN106674085B (zh) * | 2016-12-20 | 2020-06-23 | 苏州汉德创宏生化科技有限公司 | N-1,3-二氟异丙基-4-氨基哌啶类化合物的合成方法 |
| BR112021008675A2 (pt) | 2018-11-05 | 2021-08-10 | Syngenta Participations Ag | compostos de azole-amida pesticidamente ativos |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU178398B (en) | 1979-06-12 | 1982-04-28 | Gyogyszerkutato Intezet | Process for producing new agmatine derivatives of activity against haemagglutination |
| JPS57149217A (en) | 1981-03-11 | 1982-09-14 | Kaken Pharmaceut Co Ltd | Slow-releasing pharmaceutical preparation |
| HU192646B (en) | 1984-12-21 | 1987-06-29 | Gyogyszerkutato Intezet | Process for preparing new n-alkyl-peptide aldehydes |
| AU600226B2 (en) | 1985-02-04 | 1990-08-09 | Merrell Pharmaceuticals Inc. | Novel peptidase inhibitors |
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| US4792452A (en) | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US5538847A (en) * | 1989-07-17 | 1996-07-23 | Tropix, Inc. | Chemiluminescent 1,2-dioxetanes |
| EP0362002B1 (en) | 1988-09-01 | 1995-07-26 | Merrell Dow Pharmaceuticals Inc. | HIV protease inhibitors |
| ZA897515B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
| IT1229491B (it) | 1988-12-28 | 1991-09-03 | Roussel Maestretti S P A Ora R | Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali |
| TW201303B (enExample) | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| CA2075154A1 (en) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
| SE9102462D0 (sv) | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
| US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| CZ333492A3 (en) | 1991-11-12 | 1993-09-15 | Lilly Co Eli | Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised |
| SE9103612D0 (sv) | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
| DE69314478T2 (de) | 1992-03-04 | 1999-02-11 | Gyogyszerkutato Intezet Kft., Budapest | Neuartige antikoagulierende peptidderivate und arzneimittel die solche enthalten so wie entsprechendes herstellungsverfahren |
| TW223629B (enExample) | 1992-03-06 | 1994-05-11 | Hoffmann La Roche | |
| SE9301912D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | Process for the production of aminoalkylguandines |
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| US5780631A (en) * | 1993-06-03 | 1998-07-14 | Astra Aktiebolag | Starting materials in the synthesis of thrombin and kininogenase inhibitors |
| US6984627B1 (en) * | 1993-06-03 | 2006-01-10 | Astrazeneca Ab | Peptide derivatives |
| EP0648780A1 (en) | 1993-08-26 | 1995-04-19 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
| TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| AU1025795A (en) | 1994-01-27 | 1995-08-03 | Mitsubishi Chemical Corporation | Prolineamide derivatives |
| US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
| IL112795A (en) | 1994-03-04 | 2001-01-28 | Astrazeneca Ab | Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them |
| US5707966A (en) | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
| US5561146A (en) | 1994-06-10 | 1996-10-01 | Bristol-Myers Squibb Company | Modified guanidino and amidino thrombin inhibitors |
| DE4421052A1 (de) | 1994-06-17 | 1995-12-21 | Basf Ag | Neue Thrombininhibitoren, ihre Herstellung und Verwendung |
| US5498724A (en) * | 1994-06-28 | 1996-03-12 | Aktiebolaget Astra | Pyrazoleamidine compounds |
| US5510369A (en) | 1994-07-22 | 1996-04-23 | Merck & Co., Inc. | Pyrrolidine thrombin inhibitors |
| US5874298A (en) * | 1995-02-17 | 1999-02-23 | Nps Pharmaceuticals, Inc. | Insecticidal toxins from Bracon hebetor nucleic acid encoding said toxin and methods of use |
| CA2211109A1 (en) | 1995-02-17 | 1996-08-22 | Basf Aktiengesellschaft | Novel thrombin inhibitors |
| US5710130A (en) | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
| US6083532A (en) | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
| US5695781A (en) | 1995-03-01 | 1997-12-09 | Hallmark Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers |
| AU698911B2 (en) | 1995-04-04 | 1998-11-12 | Merck & Co., Inc. | Thrombin inhibitors |
| US5629324A (en) | 1995-04-10 | 1997-05-13 | Merck & Co., Inc. | Thrombin inhibitors |
| SA96170106A (ar) * | 1995-07-06 | 2005-12-03 | أسترا أكتيبولاج | مشتقات حامض أميني جديدة |
| TWI238827B (en) * | 1995-12-21 | 2005-09-01 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9601556D0 (sv) | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
| SE9602263D0 (sv) * | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
| WO1997049404A1 (en) | 1996-06-25 | 1997-12-31 | Eli Lilly And Company | Anticoagulant agents |
| SE9602646D0 (sv) * | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
| DE19632772A1 (de) * | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| SE9603724D0 (sv) | 1996-10-11 | 1996-10-11 | Astra Ab | New pharmaceutical parenteral formulation of a thrombin inhibitor |
| AR013084A1 (es) | 1997-06-19 | 2000-12-13 | Astrazeneca Ab | Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados |
| IT1297461B1 (it) | 1997-10-29 | 1999-12-17 | Ciocca Maurizio | Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili |
| SE9704401D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | Matrix pellets for greasy, oily or sticky drug substances |
| SE9704543D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
| US6174913B1 (en) * | 1998-06-05 | 2001-01-16 | The University Of North Carolina At Chapel Hill | Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents |
| SE9802938D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
| SE9802974D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | New crystalline forms |
| SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| SE9804313D0 (sv) | 1998-12-14 | 1998-12-14 | Astra Ab | New compounds |
| CA2355792A1 (en) * | 1999-01-13 | 2000-07-20 | Astrazeneca Ab | New amidinobenzylamine derivatives and their use as thrombin inhibitors |
| US6758430B1 (en) * | 1999-02-16 | 2004-07-06 | Aesop, Inc. | Method of winding motors and other electric machines to reduce AC losses |
| SE9902550D0 (sv) | 1999-07-02 | 1999-07-02 | Astra Ab | New crystalline forms |
| SE0001803D0 (sv) * | 2000-05-16 | 2000-05-16 | Astrazeneca Ab | New compounds i |
| US6433186B1 (en) * | 2000-08-16 | 2002-08-13 | Astrazeneca Ab | Amidino derivatives and their use as thormbin inhibitors |
| SE0102921D0 (sv) * | 2001-08-30 | 2001-08-30 | Astrazeneca Ab | Pharmaceutically useful compounds |
| US7129233B2 (en) * | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| AR034517A1 (es) * | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
| US6811794B2 (en) | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| SE0201661D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
| SE0201658D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
| US7781424B2 (en) | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| SE0303220D0 (sv) | 2003-11-28 | 2003-11-28 | Astrazeneca Ab | New process |
| GB0503672D0 (en) | 2005-02-23 | 2005-03-30 | Astrazeneca Ab | New process |
| GB0510546D0 (en) | 2005-05-24 | 2005-06-29 | Astrazeneca Ab | New process |
| TW200827336A (en) | 2006-12-06 | 2008-07-01 | Astrazeneca Ab | New crystalline forms |
-
2001
- 2001-11-28 AR ARP010105543A patent/AR035216A1/es active IP Right Grant
- 2001-11-29 MY MYPI20015470A patent/MY136133A/en unknown
- 2001-11-30 KR KR1020097002806A patent/KR100947296B1/ko not_active Expired - Fee Related
- 2001-11-30 EE EEP200300259A patent/EE05382B1/xx not_active IP Right Cessation
- 2001-11-30 PT PT01998535T patent/PT1347955E/pt unknown
- 2001-11-30 DE DE60141603T patent/DE60141603D1/de not_active Expired - Lifetime
- 2001-11-30 KR KR1020087014404A patent/KR100914537B1/ko not_active Expired - Fee Related
- 2001-11-30 HU HU0302487A patent/HU228814B1/hu not_active IP Right Cessation
- 2001-11-30 JP JP2002546515A patent/JP4177101B2/ja not_active Expired - Fee Related
- 2001-11-30 BR BR0115861-9A patent/BR0115861A/pt active Search and Examination
- 2001-11-30 EP EP01998535A patent/EP1347955B1/en not_active Expired - Lifetime
- 2001-11-30 DK DK01998535.7T patent/DK1347955T3/da active
- 2001-11-30 EP EP10152378A patent/EP2186800A1/en not_active Withdrawn
- 2001-11-30 AT AT01998535T patent/ATE461171T1/de active
- 2001-11-30 NZ NZ526205A patent/NZ526205A/en not_active IP Right Cessation
- 2001-11-30 PL PL362917A patent/PL207045B1/pl unknown
- 2001-11-30 ES ES01998535T patent/ES2341318T3/es not_active Expired - Lifetime
- 2001-11-30 IL IL15609601A patent/IL156096A0/xx not_active IP Right Cessation
- 2001-11-30 WO PCT/SE2001/002657 patent/WO2002044145A1/en not_active Ceased
- 2001-11-30 CN CNB018223168A patent/CN1291975C/zh not_active Expired - Fee Related
- 2001-11-30 CZ CZ20031514A patent/CZ303708B6/cs not_active IP Right Cessation
- 2001-11-30 MX MXPA03004794A patent/MXPA03004794A/es active IP Right Grant
- 2001-11-30 KR KR1020087014402A patent/KR100914535B1/ko not_active Expired - Fee Related
- 2001-11-30 CA CA2436220A patent/CA2436220C/en not_active Expired - Fee Related
- 2001-11-30 KR KR1020037007353A patent/KR100914016B1/ko not_active Expired - Fee Related
- 2001-11-30 SI SI200130965T patent/SI1347955T1/sl unknown
- 2001-11-30 SK SK651-2003A patent/SK287692B6/sk not_active IP Right Cessation
-
2003
- 2003-05-19 BG BG107825A patent/BG66261B1/bg unknown
- 2003-05-27 IS IS6828A patent/IS2755B/is unknown
- 2003-05-30 NO NO20032465A patent/NO325228B1/no not_active IP Right Cessation
-
2006
- 2006-09-13 US US11/520,052 patent/US20070218136A1/en not_active Abandoned
- 2006-09-13 US US11/520,063 patent/US7803954B2/en not_active Expired - Fee Related
-
2007
- 2007-05-04 US US11/797,656 patent/US7645751B2/en not_active Expired - Fee Related
- 2007-07-27 AU AU2007203509A patent/AU2007203509A1/en not_active Abandoned
- 2007-07-27 AU AU2007203520A patent/AU2007203520B2/en not_active Expired - Fee Related
-
2008
- 2008-01-03 NO NO20080031A patent/NO20080031L/no not_active Application Discontinuation
- 2008-01-03 NO NO20080030A patent/NO20080030L/no not_active Application Discontinuation
- 2008-01-16 JP JP2008006608A patent/JP2008156362A/ja active Pending
- 2008-01-16 JP JP2008006611A patent/JP2008138009A/ja active Pending
-
2009
- 2009-06-25 US US12/491,456 patent/US20100087651A1/en not_active Abandoned
- 2009-07-31 AR ARP090102945A patent/AR072331A2/es unknown
-
2010
- 2010-05-17 CY CY20101100436T patent/CY1113487T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004520290A5 (enExample) | ||
| RU2002127804A (ru) | Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения | |
| CA2326517A1 (en) | New galenic preparations of meloxicam for oral administration | |
| US11351191B2 (en) | Silicate containing compositions and methods of treatment | |
| WO2004112711A3 (en) | Oral extended-release composition | |
| KR20110063471A (ko) | 점막 장기간 방출형 생체부착성 치료 담체를 이용한 점막의 염증 및 염증성 통증의 치료 | |
| CA2446435A1 (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| RU98111594A (ru) | Фармацевтические композиции, включающие флурбипрофен | |
| DK1227806T3 (da) | Farmaceutisk præparat indeholdende tolterodin og dets anvendelse | |
| RU2001107149A (ru) | Тауролидин и/или таурултам против инфекционной язвенной болезни или инфекционного гастрита | |
| JP2002525266A5 (enExample) | ||
| NO20050569L (no) | Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette | |
| WO2002102743A3 (de) | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel | |
| RU97104483A (ru) | Соль янтарной кислоты 4-[2-амино-6-(циклопропиламино)-9н-пурин-9-ил]-2- циклопентен-1-метанола в качестве антивирусного агента | |
| JP2003514025A5 (enExample) | ||
| CA2552542A1 (en) | Controlled release pharmaceutical composition of tolperisone for oral administration | |
| JP2004510775A5 (enExample) | ||
| RU2006143659A (ru) | Применение ребоксетина для лечения боли | |
| RU99119233A (ru) | Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени | |
| MY137570A (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease | |
| RU2002109236A (ru) | Композиции с контрлируемым высвобождением для перорального применения | |
| WO2000066550A8 (en) | New compounds | |
| RU2185807C1 (ru) | Пролонгированные лекарственные формы местного действия, оказывающие активирующее влияние на иммунную систему | |
| EP2809316A1 (en) | Synergisctic combination comprising a meglitinide derivative and lipoic acid | |
| WO2005065641A3 (en) | Non-disintegrating oral solid composition of high dose of water soluble drugs |